Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for PT Darya-Varia Laboratoria Tbk's EV-to-FCF or its related term are showing as below:
ISX:DVLA'
s EV-to-FCF Range Over the Past 10 Years
Min: -7907.74 Med: 12.14 Max: 209.38
Current: 7.73
During the past 13 years, the highest EV-to-FCF of PT Darya-Varia Laboratoria Tbk was 209.38. The lowest was -7907.74. And the median was 12.14.
ISX:DVLA's EV-to-FCF is ranked better than 84.19% of 563
companies
in the Drug Manufacturers industry
Industry Median: 21.03
vs ISX:DVLA: 7.73
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PT Darya-Varia Laboratoria Tbk's PE Ratio (TTM) for today is calculated as:
PT Darya-Varia Laboratoria Tbk's share price for today is Rp1560.00.
PT Darya-Varia Laboratoria Tbk's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp124.307.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
PT Darya-Varia Laboratoria Tbk EV-to-FCF Related Terms
PT Darya-Varia Laboratoria Tbk EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PT Darya-Varia Laboratoria Tbk's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Darya-Varia Laboratoria Tbk EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Darya-Varia Laboratoria Tbk's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where PT Darya-Varia Laboratoria Tbk's EV-to-FCF falls into.
PT Darya-Varia Laboratoria Tbk's current Enterprise Value is Rp1,405,849 Mil.
PT Darya-Varia Laboratoria Tbk's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp179,781 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Darya-Varia Laboratoria Tbk (ISX:DVLA) has a EV-to-FCF of 7.82 as of Jul. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on PT Darya-Varia Laboratoria Tbk and its competitors. This is 36% below median its historical median of 12.14. According to the industry distribution chart, PT Darya-Varia Laboratoria Tbk ranks #89 out of 563 companies in the Drug Manufacturers industry, placing it in the top 15.8%.
Is PT Darya-Varia Laboratoria Tbk's EV-to-FCF too high?
PT Darya-Varia Laboratoria Tbk's current EV-to-FCF of 7.82 is 36% below median its 10-year median of 12.14. The Drug Manufacturers industry median EV-to-FCF is 21.03. PT Darya-Varia Laboratoria Tbk's value of 7.82 is 62.8% below this industry median. Based on the distribution chart, PT Darya-Varia Laboratoria Tbk ranks #89 out of 563 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PT Darya-Varia Laboratoria Tbk has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Darya-Varia Laboratoria Tbk's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PT Darya-Varia Laboratoria Tbk ranks #89 out of 563 companies for EV-to-FCF. This places PT Darya-Varia Laboratoria Tbk in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 21.03. PT Darya-Varia Laboratoria Tbk's value of 7.82 is 62.8% below this benchmark. While the company's 10-year median is 12.14 vs. the industry median of 21.03, PT Darya-Varia Laboratoria Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.03, based on 563 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Darya-Varia Laboratoria Tbk's current EV-to-FCF of 7.82 is 62.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on PT Darya-Varia Laboratoria Tbk and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Darya-Varia Laboratoria Tbk's current EV-to-FCF is 7.82, which is 36% below median its own 10-year median of 12.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Darya-Varia Laboratoria Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Darya-Varia Laboratoria Tbk (ISX:DVLA) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp1,845.60, compared to a current price of Rp1,560.00 — trading 15.5% below its estimated fair value. The current EV-to-FCF is 7.82, which is 36% below median its 10-year median of 12.14 and 62.8% below the Drug Manufacturers industry median of 21.03. PT Darya-Varia Laboratoria Tbk's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For PT Darya-Varia Laboratoria Tbk (ISX:DVLA), the current EV-to-FCF is 7.82 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Darya-Varia Laboratoria Tbk (ISX:DVLA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Darya-Varia Laboratoria Tbk stock appears to be undervalued.
The current stock price of Rp1,560.00 is trading 15.5% below its estimated GF Value™ of Rp1,845.60.
GuruFocus considers PT Darya-Varia Laboratoria Tbk to be Modestly Undervalued.
Key valuation signals for ISX:DVLA:
EV-to-FCF: 7.82 (36% below median its 10-year median of 12.14)
GF Value™: Rp1,845.60 vs. price of Rp1,560.00 (15.5% below fair value)
Industry Position: 62.8% below the Drug Manufacturers median (#89 of 563)
No single metric tells the full story. See the ISX:DVLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Darya-Varia Laboratoria Tbk Business Description
PT Darya-Varia Laboratoria Tbk (Darya-Varia) is operating in the pharmaceutical industry. It is engaged in the manufacture and trade of pharmaceutical products, human, traditional medicines, pharmaceutical materials, raw materials for traditional medicines, inorganic base chemicals, organic base chemicals, equipment for surgery, medical and dental care, and equipment, orthopedic equipment, prosthetic, eyeglasses, laboratory and health equipment from glass, cosmetics, wholesaler of pharmaceutical, traditional medicine, chemical base materials, laboratory testing services, periodic inspection services, and many more activities. Its business segments include: prescription drugs; consumer health products, which derives key revenue; export and toll manufacturing services; and services.
73GF Score
Get the complete analysis for ISX:DVLA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:DVLA has been successfully added to your 
